Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05214209
Other study ID # PRIME (pilot)
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date March 1, 2022
Est. completion date December 2024

Study information

Verified date March 2023
Source Monash University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Currently, an estimated 3.9 million Malaysians continue to live with diabetes with many more who live with prediabetes. Diabetes was the one of the leading causes of death in the Malaysia and the leading cause for kidney failure, lower-limb amputations, and adult-onset blindness. Heart disease and stroke are two to four times more likely for individuals with diabetes. The use of mHealth or mobile health application can reduce blood sugar among individuals with prediabetes but also prevent a later occurrence of diabetes. In this study, the investigators aim to develop and evaluate the effectiveness of a digital health supported pre-diabetes management program based in an urban community pharmacy setting


Description:

Pre-diabetes is an intermediate state of hyperglycaemia with glycaemic parameters above normal but below the type 2 diabetes mellitus (T2DM) threshold. It was estimated that >25% of individuals who are pre-diabetic convert to T2DM within 3-5 years and 70% of individuals with pre-diabetes will develop into full-fledge T2DM within their lifetimes. According to the 2017 estimate, the disease burden of pre-diabetes at Western Pacific region was 7.6% (126.7 millions). The situation is more alarming in Malaysia where a national pre-diabetes prevalence of 22.1% was noted. Currently available support and self-care services offered in Public Hospitals such as the Diabetes Mellitus Treatment Adherence Clinics (DMTAC) are managed based on the in-person appointment basis. Most of the clinics are available only in specific locations. The need to travel long distance as well as long waiting hours has deterred the success of the programs. This is particularly true for the urban poor who are less likely to take time off from work than those from the higher income group. It is also noteworthy to state that the management program when available, generally target the diagnosed T2DM patients. Studies have shown that individuals with pre-diabetes can substantially reduce their risk of progression to T2DM via participation in evidence-based lifestyle change programs. Previous reports have recorded 54-58% reduction in risk for development to T2DM over 1-3 years with the protective benefit persisting up to 10 years following completion of the program. However, there are several considerations when implementing effective lifestyle intervention program among the pre-diabetes populations in Malaysia. The intervention program should easily be accessible and not confined to public primary and secondary healthcare centres which are already suffering from an overcapacity. Furthermore, consultation should be provided by properly trained healthcare professionals while the ease of communication between the patients and the "lifestyle coach" should be made available. The advancement of information technology coupled with the increasing availability and acceptance of internet and mobile devices provide useful opportunities for application of wireless and mobile technology in order to enhance self-management of chronic conditions. The incorporation of digital technologies can improve patient adherence and facilitate real-time monitoring of vital biological measurements (i.e. via wearable). Additionally, the "mobile health" (mHealth) services are easily scalable, thus providing opportunities to a greater public accessibility and narrow the disparity in access to disease management. In this study, the investigators propose to pilot a digital health supported pre-diabetes management program based in an urban community pharmacy setting


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 10
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Aged 18 years and above - BMI 23 and above - HbA1c 5.7 - 6.3% Exclusion Criteria: - Unable to give informed consent - Pregnant or lactating - Established diabetes - Terminal illness - Does not own a mobile phone - Plans to relocate to an area or travel plans that do not permit full participation in the study

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Digital health supported
Participants will be issued a fitness tracker, a Bluetooth enabled glucometer, and a custom developed app which they can communicate digitally to the study investigators either as a group or individually. In the beginning of the study, participants will be taught on how to use the program, how to interact with their coach, and the importance of maintaining motivation throughout the program. Participants will have access to a pharmacist-participant messaging, group messaging, daily challenges for behavior change, education articles (weekly bite-sized content over 4 weeks), food logging, steps and exercise logging, and feedback. They will be asked to log their weight, meals, and physical activity within the program on a weekly basis. Pharmacist will monitor participant progress through a web-based dashboard. Community pharmacist will be assisting users in setting specific, measurable, attainable, realistic, and time-based goals on a weekly basis.
Usual care
Participants will be issued a fitness tracker and Bluetooth enabled glucometer but these functions will not be enabled or linked to any app. All participants will be given physical tracking sheets to log in their food intake, blood glucose levels and food diary but will not have access to a personal coaching. Participants are free to seek any assistance for their medical care during the study period.

Locations

Country Name City State
Malaysia School of Pharmacy Subang Jaya Selangor

Sponsors (3)

Lead Sponsor Collaborator
Monash University Bionime Corporation, Caring Pharmacy

Country where clinical trial is conducted

Malaysia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of mobile app assessed by the engagement rate with the mobile app Engagement rate with the mobile app will be measured via time spend on using the app functions, measured in hours. 1 month
Primary Acceptability of mobile app assessed by a semi-structured interview Semi-structured interview focusing on users experience will be conducted post-intervention. 1 month
Secondary Change in health related quality of life as accessed by EuroQol (EQ-5D-5L) The questionnaire assess patient's health state in 5 dimensions- anxiety/depression, mobility, self-care, usual activities, pain/discomfort. Each dimension can be scored from 1 - 5, summing up to a total score of between 5 - 25. A lower score representing a better health state. Baseline, 1 month
Secondary Change in dietary practice 3-Day diet recall to assess changes in food intake Baseline, 1 month
Secondary Change in physical activity Physical Activity Questionnaire (short form) (IPAQ) to obtain internationally comparable data on health-related physical activity. Time spent on physical activities will be measured and converted into metabolic equivalent for task (MET). A lower MET indicates a lower physical activity level. Baseline, 1 month
Secondary Change in blood pressure Systolic and diastolic pressures will be collected during the study period, unit in mmHg Baseline, 1 month
Secondary Change in lipid profile HDL, LDL, triglycerides and total cholesterol levels will be collected, unit in mmol/L Baseline, 1 month
Secondary Change in knowledge, attitude and practice towards prediabetes Knowledge Attitude Practice-Prediabetes Assessment Questionnaire (KAP-PAQ) questionnaire will be administered pre- and post intervention. The minimum total score is 14 while the maximum total score is 91. A higher score indicating a better knowledge, attitude and practice. Baseline, 1 month
Secondary Change in weight Weight Loss by % of change and total weight change (kg). Baseline, 1 month
Secondary Change in body fat composition Body fat composition change measured in % change. Baseline, 1 month
Secondary Change in waist-to-hip ratio Waist circumference and hip circumference measured in centimetres. Baseline, 1 month
See also
  Status Clinical Trial Phase
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Completed NCT03188263 - Morning Light Treatment to Improve Glucose Metabolism N/A
Recruiting NCT03821961 - 18F-FDOPA PET/CT Imaging in Patients Undergoing Metabolic Surgery N/A
Completed NCT04303468 - Intervention With a GABA Supplement in Prediabetics N/A
Recruiting NCT06094231 - Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study N/A
Completed NCT03675360 - Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial N/A
Completed NCT01910051 - Explorative Assessment of Biomarkers in Overweight and Obese Subjects
Completed NCT03527368 - The Time-Restricted Intake of Meals Study N/A
Completed NCT03865342 - Prevention of Diabetes Using Mobile-enabled, Virtual Delivery of the National Diabetes Prevention Program N/A
Suspended NCT03240978 - Exercise Intervention for the Prevention of Prediabetes in Overweight Chinese N/A
Completed NCT02899390 - Diabetes Prevention Program in Adults of the Yaqui Tribe of Hermosillo, Sonora at Risk of Diabetes N/A
Recruiting NCT01972113 - Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study) N/A
Completed NCT01432509 - Prospective Follow-up of a Cohort of Pre-diabetics in the North of France (DiabeNord) N/A
Completed NCT01436916 - Oral Cholecalciferol in Prevention of Type 2 Diabetes Mellitus Phase 4
Completed NCT00990184 - Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes) Phase 3
Completed NCT00886340 - A Lifestyle Change Program to Prevent Type 2 Diabetes Phase 2
Not yet recruiting NCT05658770 - Efficacy of Physical Exercise on Glucose Control in People With Prediabetes (GLYCEX) - Phase II N/A